0
Original Research: Genetic and Developmental Disorders |

Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung DiseaseIvacaftor in Severe Cystic Fibrosis

Peter J. Barry, MBBCh; Barry J. Plant, MD; Arjun Nair, MBChB; Stephen Bicknell, MBChB; Nicholas J. Simmonds, MD; Nicholas J. Bell, MBChB; Nadia T. Shafi, MD; Thomas Daniels, MD; Susan Shelmerdine, MBBS; Imogen Felton, MBBS; Cedric Gunaratnam, MBBCh; Andrew M. Jones, MD; Alex R. Horsley, PhD
Author and Funding Information

From the University Hospital of South Manchester NHS Foundation Trust (Drs Barry, Jones, and Horsley), Manchester, England; Royal College of Physicians of Ireland (Dr Barry), Dublin, Ireland; Cork University Hospital (Dr Plant), University College Cork, Cork, Ireland; Royal Brompton Hospital and Imperial College (Drs Nair, Simmonds, Shelmerdine, and Felton), London, England; Gartnavel General Hospital (Dr Bicknell), Glasgow, Scotland; Bristol Adult Cystic Fibrosis Centre (Dr Bell), Bristol, England; Papworth Hospital (Dr Shafi), Cambridge, England; University Hospital Southampton (Dr Daniels), Southampton, England; Beaumont Hospital (Dr Gunaratnam), Dublin, Ireland; and the University of Manchester, Manchester Academic Health Science Centre (Dr Horsley), University Hospital of South Manchester NHS Foundation Trust, Manchester, England.

CORRESPONDENCE TO: Alex R. Horsley, PhD, Manchester Adult Cystic Fibrosis Center, University Hospital of South Manchester, Wythenshawe, Manchester, M23 9LT, England; e-mail: alexander.horsley@manchester.ac.uk


FUNDING/SUPPORT: This study was supported by the Manchester Adult Cystic Fibrosis Centre. Dr Horsley is funded by a National Institute for Health Research Clinician Scientist award [NIHR CS012-013].

Some of the data included in this manuscript have been published in abstract form (Barry P, Plant B, Nair A, et al. J Cyst Fibros. 2013;12[1]:S15 and Barry P, Plant B, Simmonds NJ, et al. J Cyst Fibros. 2013;12[1]:S62) and presented at the European Cystic Fibrosis Conference, June 12-15, 2013, Lisbon, Portugal, and at the North American Cystic Fibrosis Conference, October 17-19, 2013, Salt Lake City, UT.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2014;146(1):152-158. doi:10.1378/chest.13-2397
Text Size: A A A
Published online

BACKGROUND:  The development of ivacaftor represents a significant advance in therapeutics for patients with cystic fibrosis (CF) who carry the G551D mutation. Patients with an FEV1 < 40% predicted represent a considerable proportion of eligible patients but were excluded from phase 3 clinical trials, and the effectiveness of the drug in this population is, therefore, unknown.

METHODS:  Data were collected from adult CF centers in the United Kingdom and Ireland with patients enrolled in an ivacaftor compassionate use program (FEV1 < 40% or on lung transplant waiting list). Clinically recorded data were collated from patient records for 1 year prior and for a period of 90 to 270 days following ivacaftor commencement. Each patient was matched to two control subjects who would have met the requirements for the compassionate use program with the exception of genotype.

RESULTS:  Twenty-one patients received ivacaftor for a median of 237 days. Mean FEV1 improved from 26.5% to 30.7% predicted (P = .01), representing a 16.7% relative improvement. Median weight improved from 49.8 to 51.6 kg (P = .006). Median inpatient IV antibiotic days declined from 23 to 0 d/y (P = .001) and median total IV treatment days decreased from 74 to 38 d/y (P = .002) following ivacaftor. Changes in pulmonary function and IV antibiotic requirements were significant compared with control subjects.

CONCLUSIONS:  Ivacaftor was clinically effective in patients with CF who carry the G551D mutation and have severe pulmonary disease. The reductions in treatment requirements were clinically and statistically significant and have not been described in less severe populations.

Figures in this Article

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.
Want to access your Institution's subscription?
Sign in to your individual user account while you are actively authenticated on this website via your institution (Learn more about institutional authentication). We will then sustain your personal access to their content/subscription for 90 days, after which you can repeat this process.

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Update in cystic fibrosis 2013. Am J Respir Crit Care Med 2014;189(10):1181-6.
Guidelines
Infant/toddler pulmonary function tests-2008 revision & update.
American Association for Respiratory Care | 4/3/2009
Removal of the endotracheal tube—2007 revision & update.
American Association for Respiratory Care | 8/17/2007
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543